Skip to content
Screener

AbCellera Biologics Inc. ABCL Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
-$44.09M-12.1%
Ginkgo Bioworks logo
Ginkgo BioworksDNA
-$46.95M+18.8%
Absci Corporation logo
Absci CorporationABSI
-$33.36M-10.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$36.94M-77.6%
Xencor logo
XencorXNCR
-$22.63M+26.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$53.01M-34.3%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$2.12B+57.4%
Enterprise value$2.11B+53.8%
P/S32×-8.9×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046
Line itemThree months ended June 30, 2025Three months ended June 30, 2026Six months ended June 30, 2025Six months ended June 30, 2026
Income tax recovery(1,617)(3,538)(8,980)(9,909)
Net loss$(34,727)$(55,427)$(80,348)$(98,592)
Foreign currency translation adjustment4,341(733)1,7211,082
Comprehensive loss$(30,386)$(56,160)$(78,627)$(97,510)
Net loss per share
Basic$(0.12)$(0.18)$(0.27)$(0.32)
Diluted$(0.12)$(0.18)$(0.27)$(0.32)
Weighted-average common shares outstanding

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s comprehensive income (loss), net of tax, attributable to parent?
AbCellera Biologics Inc. (ABCL) reported comprehensive income (loss), net of tax, attributable to parent of -$56.16M in Q2 2026.
How has AbCellera Biologics Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
AbCellera Biologics Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 84.8% year-over-year, from -$30.39M to -$56.16M.
What is the long-term trend for AbCellera Biologics Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2021 to 2025), AbCellera Biologics Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a -1.6% compound annual growth rate (CAGR), from $153.75M to -$146.27M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This represents the total change in equity during a period resulting from transactions and other events from non-owner sources, including net income and other comprehensive income items. It provides a more holistic view of financial performance by including unrealized gains or losses that are excluded from standard net income. Investors use this to evaluate the total economic impact of all financial activities on shareholder value.

Ask your AI about AbCellera Biologics Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude